Pituitary Cancer Market Analysis

Global Pituitary Cancer Market Overview

Pituitary cancer Market Size was valued at USD 0.31 Billion in 2023. The Global Pituitary cancer industry is projected to grow from USD 0.34 Billion in 2024 to USD 0.64 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.20% during the forecast period (2024 - 2032).

Pituitary cancer is a type of cancer that develops in the pituitary gland, which is located behind the nose. Pituitary cancer is an uncommon malignancy, with just a few hundred instances reported worldwide. This disease is mostly found in the elderly, and 75 percent of pituitary cancer cases are discovered after the person has died. 

According to the American Brain Tumor Association, benign tumors make up 30 percent to 40% of all pituitary tumor cases. This tumor is most commonly found in women and men between the ages of 40 and 50. A benign pituitary tumor (adenoma), which is non-cancerous, affects one out of every four people. The majority of pituitary tumors are harmless and curable. Pituitary tumors account for between 12% and 19% of all primary brain cancers leading to Pituitary cancer Market Growth.

Pituitary cancer is difficult to detect, which has prompted the development of more accurate and efficient detection methods. MRI or CT scans, as well as blood and urine tests, can be used to detect malignancies in the pituitary gland. The malignant pituitary cancer, on the other hand, is difficult to detect until it has spread to another portion of the body. Metastatic pituitary cancer occurs when pituitary cancer spreads to locations inside and outside the brain. 

The spinal cord, brain blood vessels, surrounding bone, lymph nodes, and organs such as the lungs, heart, pancreas, and liver are also common sites. Pituitary carcinoma is a type of cancer in which the pituitary gland grows abnormally. It affects the pituitary gland's function and can result in an increase or decrease in pituitary hormone production in the body.

COVID Analysis

Physicians of many specialties have been impacted, both emotionally and professionally, as a result of screening for and treating patients with COVID-19, which was outside their area of competence, as well as postponing care for patients with acute and chronic diseases caused by other maladies. Furthermore, COVID-19 has resulted in the emergence of new diseases, putting some patients with chronic illnesses in danger. COVID-19 has a strong relationship with pituitary illnesses and numerous disease components, such as acute vision loss, tumor mass effects, or chronic problems including adrenal insufficiency (AI), hypopituitarism, or growth hormone (GH) excess (acromegaly) increasing Pituitary cancer Market Share. 

Furthermore, many individuals with severe SARS-CoV-2 are being treated with substantial doses of glucocorticoids despite having no history of pituitary problems. This is based on evidence that suggests aberrant immune response, rather than uncontrolled virus replication, may cause extra lung damage and progression to severe respiratory failure. Another link between COVID-19 and pituitary issues is the advice that many patients with fractures should begin early bone-targeted treatment, even while in the hospital, in addition to calcium and vitamin D administration. Due to restricted resources, which result in early discharge during the COVID-19 pandemic, this can be difficult. This all thing has any hoe increased the Pituitary Cancer Market Trends.

Pituitary Cancer Market Trends

Drivers

Pituitary cancer Market Growth is likely to be fueled by factors such as the increased prevalence of pituitary cancer. Furthermore, rising oncology research and development expenditures for the discovery of novel medications to treat cancer are likely to drive pituitary cancer market value. For example, Memorial Sloan Kettering Cancer Center began a phase II study of nivolumab with ipilimumab immunotherapy in patients with aggressive pituitary tumors during the historic prediction period. As a result, the market is driven by research and development activities. The increased incidence of pituitary cancer is expected to enhance the market. According to the National Brain Tumor Society, there are 78,980 new cases of non-malignant, primary malignant, and other central nervous system tumors diagnosed in the United States each year. Thus, during the projected period, the rising number of incidences of brain tumors is expected to boost the market.

Restraints

The Pituitary Cancer Market trend is expected to benefit from increased usage and availability of diagnostic tests around the world. Furthermore, in some circumstances, drugs are preferred for the treatment of pituitary cancers. Following surgery or radiation therapy, a limited number of drugs are given.

Diagnostic techniques in established economies, such as the United States and Europe, are more advanced than in underdeveloped economies. However, increased awareness of numerous diagnostic tests for Pituitary cancer Market Share is projected to accelerate uptake in Asia and Latin America's growing economies. Because benign tumors are the most common type of pituitary cancer, diagnostic tests are used to identify them. Furthermore, experience in radiation therapy and operations is likely to make a pituitary cancer treatment effective. For any type of brain tumor, including pituitary cancers, surgery has remained the most preferred first treatment and increased market size. Furthermore, thanks to technical improvements, radiation therapy for pituitary tumors is gaining popularity around the world as a non-invasive innovative therapeutic option during the forecast period.

Pituitary Cancer Market Segmentation

Pituitary cancer market cancer type outlook

• Adrenocorticotropic Hormone-Secreting (ACTH) Tumor


• Growth Hormone-Secreting Tumor


• Prolactin-Secreting Tumor


• Thyroid-Stimulating Hormone-Secreting Tumor

Pituitary cancer market treatment type outlook

• Chemotherapy


• Surgery


• Endoscopic Trans Nasal Transsphenoidal Surgery


• Craniotomy


• Radiation Therapy


• Stereotactic Radiosurgery


• External Beam Radiation


• Intensity-Modulated Radiation Therapy (IMRT)


• Proton Beam Therapy


• Others

Pituitary cancer market end-user outlook

• Hospitals & Clinics


• Specialty Clinics


• Others

Pituitary Cancer Market Regional Classification

Because of the rising prevalence of pituitary cancer and the presence of major market players in the region, such as Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Merck & Co., Inc., and Pfizer Inc., the Americas are expected to dominate the global Pituitary cancer Market Analysis.

Because of the existence of key market participants such as AstraZeneca, Novartis AG, GlaxoSmithKline plc, Onex, and Ipsen Pharmaceuticals, Europe is likely to hold the second-largest proportion of the market. Furthermore, increased R&D initiatives for the development of enhanced pituitary cancer treatment alternatives are projected to propel the market.

Due to rising awareness of various types of cancer, including pituitary cancer, rising incidence rates of pituitary cancer, and increased Research & Development in the field of oncology, Asia-Pacific is predicted to be the fastest-growing regional market.

Due to a lack of awareness about cancer, the pituitary cancer market in the Middle East and Africa is likely to grow slowly throughout the forecast period

Americas

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Latin America

Europe

• Western Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • Italy
  
  
  • Spain
  
  
  • UK
  
  
  
  


• Rest of Western Europe


• Eastern Europe

Asia-Pacific

• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific

The Middle East & Africa

• Middle East


• Africa

Pituitary Cancer Market Competitive Landscape

Product launches, mergers and acquisitions, partnerships, and collaborations are among the methods used by key competitors to contribute to the global growth of the pituitary cancer market. People are getting more informed as a result of greater government initiatives, which are moving the market upward. The industry's growth is also projected to be boosted by strategic agreements and new product launches by major firms. The major key players of the market are as follows:

• Amgen Inc. (US)


• Astellas Pharma Inc. (Japan)


• Eli Lilly and Company (US)


• Bristol-Myers Squibb Company (US)


• Celgene Corporation (US)


• Merck & Co., Inc. (US)


• Novartis AG (Switzerland)


• Pfizer Inc. (US), AstraZeneca (UK)


• Mylan N.V. (US)


• Johnson & Johnson Services, Inc. (US)


• Onxeo (France)


• Ipsen Pharmaceuticals (France)


• Salix Pharmaceuticals, Inc. (US)


• Strides Pharma Science Limited (India)

Recent Developments

Tiburio Therapeutics Inc. was founded by Cydan to research therapies for uncommon neuroendocrine tumors and endocrine illnesses.

The National Institute of Diabetes and Digestive and Kidney Diseases has awarded Crinetics Pharmaceuticals, Inc. a Phase IIB Small Business Innovation Research (SBIR) grant for up to USD 2.8 million.

Pituitary Cancer Market Report Overview

The study's findings Visualize the worldwide pituitary cancer market's composition by diagnosis, treatment type, and end-user, highlighting the market's most important commercial assets and players. the research Analyze trends and co-development deals to identify commercial prospects in the global pituitary cancer industry. The overall picture presented in the research depicts the current market scenario in great detail, including historical and predicted market sizes in terms of value and volume, technical advancements, macroeconomic factors, and market regulatory aspects. The analysis in the report offers detailed information and plans for the market's top major players. It also provides a high-level overview of the key market segments and regions.